HLS Therapeutics Inc. (TSX:HLS)

Market Cap	134.48M
Revenue (ttm)	81.47M
Net Income (ttm)	-28.28M
Shares Out	31.79M
EPS (ttm)	-0.89
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,305
Average Volume	14,770
Open	4.230
Previous Close	4.230
Day's Range	4.230 - 4.440
52-Week Range	3.000 - 4.980
Beta	1.01
RSI	48.81
Earnings Date	May 8, 2025

About HLS Therapeutics

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders, central nervous system, and cardiovascular disease in Canada, the United States, and internationally. The company’s lead products include Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care de...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Craig Millian
• Employees: 92
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: HLS

Financial Performance

In 2024, HLS Therapeutics's revenue was $56.62 million, a decrease of -10.23% compared to the previous year's $63.07 million. Losses were -$19.66 million, -28.61% less than in 2023.

Financial numbers in USD